Polaris Pharmaceuticals-KY: Announcement of commitments made by the company during its stock listing application and subsequent execution status

AI Summary (NQ-processed)

Polaris Pharmaceuticals-KY announced on April 7, 2026, the commitments made during its stock listing application to the Taiwan Stock Exchange and their execution status. These commitments include disclosing information on new drug R&D, CDMO business, and funding needs in the prospectus, extending the centralized custody period for shares to three years, and removing provisions for independent directors to convene shareholder meetings. These have been implemented through prospectus disclosure, share submission, and amendment of the company's articles of association.